Peroxisome Proliferator-Activated Receptor-γ gene polymorphisms are not associated with osteonecrosis of the femoral head in the Korean population

Molecules and Cells

Volumn 24, Issue 3, 2007, Pages 388-393

  Kim, Tae Ho ^a,b   Hong, Jung Min ^a   Park, Eui Kyun ^a,c   Kim, Shin Yoon ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

Adipogenesis; Femoral head; Osteonecrosis; Polymorphism; PPAR

Indexed keywords

ALANINE; HISTIDINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREDNISOLONE; PROLINE; STEROID;

ADULT; ALLERGIC ASTHMA; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; FEMALE; FEMUR HEAD NECROSIS; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; NUCLEOTIDE SEQUENCE; ORGAN TRANSPLANTATION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; FEMUR HEAD NECROSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KOREA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PPAR GAMMA;

EID: 38348999078     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Abu-Shakra, M., Buskila, D., and Shoenfeld, Y. (2003) Oateonecrosis in patients with SLE. Clin. Rev. Allergy Immunol. 25, 13-24.
2. Ali, A. A., Weinstein, R. S., Stewart, S. A., Parfitt, A. M., Manolagas, S. C., et al. (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146, 1226-1235.
3. Antoine, H. J., Pall, M., Trader, B. C., Chen, Y. D., Azziz, R., et al. (2007) Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertil. Steril. 87, 862-869.
4. Assouline-Dayan, Y., Chang, C., Greenspan, A., Shoenfeld, Y., and Gershwin, M. E. (2002) Pathogenesis and natural history of osteonecrosis. Semin. Arthritis Rheum. 32, 94-124.
5. Atsumi, T. and Kuroki, Y. (1992) Role of impairment of blood supply of the femoral head in the pathogenesis of idiopathic osteonecrosis. Clin. Orthop. Relat. Res. 227, 22-30.
6. Backesjo, C. M., Li, Y., Lindgren, U., and Haldosen, L. A. (2006) Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J. Bone Miner. Res. 21, 993-1002.
7. Bowers, J. R., Dailiana, Z. H., McCarthy, E. F., and Urbaniak, J. R. (2004) Drug therapy increases bone density in osteonecrosis of the femoral head in canines. J. Surg. Orthop. Adv. 13, 210-216.
8. Buzzetti, R., Petrone, A., Caiazzo, A. M., Alemanno, I., Zavarella, S., et al. (2005) PPAR-gamma Pro12Ala variant is associated with greater insulin sensitivity in childhood obesity. Pediatr. Res. 57, 138-140.
9. Cui, Q., Wang, G. J., Su, C. C., and Balian, G. (1997) The Otto Aufranc Award. Lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin. Orthop. Relat. Res. 344, 8-19.
10. de Camargo, F. P., de Godoy, R. M., Jr., and Tovo, R. (1984) Angiography in Perthes' disease. Clin. Orthop. Relat. Res. 191, 216-220.
11. Deeb, S. S., Fajas, L., Nemoto, M., Pihlajamaki, J., Mykkanen, L., et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20, 284-287.
12. Doney, A. S., Fischer, B., Cecil, J. E., Boylan, K., McGuigan, F. E., et al. (2004) Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 47, 555-558.
13. Fisher, D. E. (1978) The role of fat embolism in the etiology of corticosteroid-induced avascular necrosis: clinical and experimental results. Clin. Orthop. Relat. Res. 130, 68-80.
14. Gardeniers, J. W. M. (1993) The ARCO perspective for reaching one uniform staging system of osteonecrosis; in Bone Circulation and Vascularization in Normal and Pathologic Conditions, Scoutens, A., Arlet, J, Gardeniers, J. W. M., and Hughes, S. P. F. (eds.), pp. 375-380, Plenum Press, New York.
15. Glueck, C. J., Freiberg, R. A., and Wang, P. (2003) Role of thrombosis in osteonecrosis. Curr. Hematol. Rep. 2, 417-422.
16. Hedrick, P. W. (1987) Gametic disequilibrium measures: proceed with caution. Genetics 117, 331-341.
17. Ishida, Y. and Heersche, J. N. (1998) Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J. Bone Miner. Res. 13, 1822-1826.
18. Jaziri, R., Lobbens, S., Aubert, R., Pean, F., Lahmidi, S., et al. (2006) The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the data from an epidemiological study on the insulin resistance syndrome (DESIR) study. Diabetes 55, 1157-1162.
19. Jones, J. P., Jr. (1992) Intravascular coagulation and osteonecrosis. Clin. Orthop. Relat. Res. 277, 41-53.
20. Jones, J. P., Jr. (1993) Fat embolism, intravascular coagulation, and osteonecrosis. Clin. Orthop. Relat. Res. 292, 294-308.
21. Jones, L. C., Mont, M. A., Le, I B., Petri, M., Hungerford, D. S., et al. (2003) Procoagalants and osteonecrosis. J. Rheumatol. 30, 783-791.
22. Kerachian, M., Harvey, E., Cournoyer, D., Chow, T., and Seguin, C. (2006) Avascular necrosis of the femoral head: vascular hypotheses. Endothelium 13, 237-244.
23. Kersten, S., Desvergne, B., and Wahli, W. (2000) Roles of PPARs in health and disease. Nature 405, 421-424.
24. Knoblauch, H., Busjahn, A., Muller-Myhsok, B., Faulhaber, H. D., Schuster, H., et al. (1999) Peroxisome proliferator-activated receptor gamma gene locus is related to body mass index and lipid values in healthy nonobese subjects. Arterioscler. Thromb. Vasc. Biol. 19, 2940-2944.
25. Koo, K. H., Kim, R., Kim, Y. S., Ahn, I. O., Cho, S. H., et al. (2002) Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment. Clin. Rheumatol. 21, 299-303.
26. Liu, Y. F., Chen, W., M., Lin, Y. F., Yang, R. C., Lin, M. W., et al. (2005) Type II collagen gene variants and inherited osteonecrosis of the femoral head. N. Engl. J. Med. 352, 2294-2301.
27. Margeli, A., Kouraklis, G., and Theocharis, S. (2003) Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis 6, 165-169.
28. Matsui, M., Saito, S., Ohzono, K., Sugano, N., Saito, M., et al. (1992) Experimental steroid-induced osteonecrosis in adult rabbits with hypersensitivity vasculitis. Clin. Orthop. Relat. Res. 277, 61-72.
29. Meirhaeghe, A., Fajas, L., Helbecque, N., Cottel, D., Lebel, P., et al. (1998) A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum. Mol. Genet. 7, 435-440.
30. Nuttall, M. E., Patton, A. J., Olivera, D. L., Nadeau, D. P., and Gowen, M. (1998) Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J. Bone Miner. Res. 13, 371-382.
31. Ogawa, S., Urano, T., Hosoi, T., Miyao, M., Hoshino, S., et al. (1999) Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem. Biophys. Res. Commun. 260, 122-126.
32. Pritchett, J. W. (2001) Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin. Orthop. Relat Res. 386, 173-178.
33. Qin, Z. S., Niu, T., and Liu, J. S. (2002) Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am. J. Hum. Genet. 71, 1242-1247.
34. Rosen, C. J. and Bouxsein, M. L. (2006) Mechanisms of disease: is osteoporosis the obesity of bone? Nat. Clin. Pract. Rheumatol. 2, 35-43.
35. Rosen, E. D. and Spiegelman, B. M. (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276, 37731-37734.
36. Takano, H. and Komuro, I. (2002) Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease. J. Diabetes Complications 16, 108-114.
37. Wang, G. J., Sweet, D. E., Reger, S. I., and Thompson, R. C. (1977) Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits. J. Bone Joint. Surg. Am. 59, 729-735.
38. Wang, Y., Li, Y., Mao, K., Li, J., Cui, Q., et al. (2003) Alcohol-induced adipogenesis in bone and marrow: a possible mechanism for osteonecrosis. Clin. Orthop. Relat. Res. 410, 213-224.
39. Yki-Jarvinen, H. (2004) Thiazolidinediones. N. Engl. J. Med. 351, 1106-1118.
40. Zizic, T. M., Marcoux, C., Hungerford, D. S., Dansereau, J. V., and Stevens, M. B. (1985) Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am. J. Med. 79, 596-604.